Biogen (BIIB) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Biogen (BIIB) is Neutral.

The composite score behind that read is +0.13, weighing +0.21 of bullish evidence against -0.36 bearish.

Biogen last closed at $225.71, +3.33% on the session.

Against the IVW growth benchmark the position is +2.53% over the forecast window.

The read is built from 15 underlying insights — 9 bullish and 6 bearish.

Agreement across those insights is 60%.

Biogen has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Biogen in the 20th percentile on valuation and the 47th percentile on return on equity, where 100 is best.

Biogen is classified under Health Care / Biotechnology, with a market capitalisation of $32.27B.

StockMap tracks Biogen as the 11th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Biogen ranks 34th of 381 in the group, against a group median of -0.08.